invention thioredoxin-binding protein (thioredoxin-binding protein TXNIP) the active ingredients contained in the immunity enhancement, inhibiting cancer metastasis, and blood diseases for the prevention and treatment of the composition by, more specifically, in TXNIP deficient mice decreased the frequency of hematopoietic stem cells, and bone marrow and the reduced proliferative capacity, through bone marrow transplantation TXNIP deficient mice was confirmed to decrease the proliferative capacity of bone marrow-derived cells. In addition, the increased levels of free radicals and oxidative stress induced cell death in the conditions under TXNIP knockout mice and TXNIP deficient cell line, it was confirmed that the proliferative capacity of bone marrow TXNIP knockout mouse-derived cell line is reduced. In addition, cancer metastasis was confirmed that an increase in the oxidative stress in the conditions under TXNIP knockout mice, it was confirmed that the expression of p53 decreased. In addition, the direct bond was confirmed positioned between TXNIP and p53, and the binding is increased under conditions of oxidative stress, which results increased the transcriptional activity of p53- mediated, also, by ensuring that the increased antioxidant activity p53- mediated of the present invention TXNIP gene delivery system, cells or proteins containing the gene TXNIP the immunity enhancement, cancer metastasis suppressor, and blood disorders can be effectively used as a composition for prevention and treatment.본 발명은 티오레독신-결합 단백질(thioredoxin-binding protein TXNIP)을 유효성분으로 포함하는 면역증강, 암 전이억제, 및 혈액질환 예방 및 치료용 조성물에 관한 것으로, 보다 구체적으로, TXNIP 결핍 마우스에서 조혈모세포의 빈도가 감소하고, 골수증식 능력이 감소하며, 골수이식을 통해 TXNIP 결핍 마우스-유래 골수세포의 증식능력이 감소하는 것을 확인하였다. 또한, 산화적 스트레스 조건하의 TXNIP 녹아웃 마우스 및 TXNIP 결핍 세포주에서 활성산소의 수준이 증가하고, 세포사멸을 유도하며, 상기 TXNIP 녹아웃 마우스 유래 세포주의 골수증식 능력이 감소하는 것을 확인하였다. 또한, 산화적 스트레스 조건하의 TXNIP 녹아웃 마우스에서 암 전이가 증가하는 것을 확인하였고, p53의 발현이 감소함을 확인하였다. 또한, TXNIP 및 p53 사이에 직접적인 결합 위치를 확인하였고, 상기
